In The Spotlight
DDNews Cancer Research Exclusive
 
 
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
 
(Photo credit: University of Toronto)
 
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
 
 
NEWS
Merck's Keytruda racks up yet another FDA approval—this time as a combination with Inlyta for patients with renal cell carcinoma
 
Researchers pinpoint a mechanism by which colorectal cancer cells can evade immunotherapy
 
MOR208 clinical trial results promising and drug is on fast track to FDA approval, company says
 
Transgene announced plans to move its lead candidate, TG4050, into clinical development
 
Company aims to develop cancer immunotherapy candidate, which is a selective inhibitor of TGFβ1 activation
 
Florida researchers say potential avenue for cancer treatment could be hiding in microscopic ‘molecular machine’
 
Florida researchers say potential avenue for cancer treatment could be hiding in microscopic ‘molecular machine’
 
Adaptimmune presents preclinical data for its next-generation SPEAR T cell
 
  
FEATURES
 
 
Glioblastoma remains a difficult cancer to treat, but the brain malignancy is seeing increasing attention in R&D
 
OPINION
Guest Commentary: A tale of safety and consistency
by Charles River Laboratories
Drs. Ulrike Herbrand, Christopher Sucato and Alvaro Jorge Amor of Charles River Laboratories discuss the challenges of bringing antibody-drug conjugates to market

Guest Commentary: Opportunities for personalized cancer immunotherapy directed by immune-profiling
by S. Anderton and M. Millar
There are currently three main approaches to characterizing the immune landscape of solid tumors: transcriptional profiling, single-cell cytometric analyses and histology; each of these disciplines brings its own benefits and, with rapid technological advances, powerful datasets are now achievable.

Guest Commentary: A more reproducible approach to creating functional Th17 cells
by Kevin Bobofchak of Lonza
A look at the importance of Th17 cells for drug discovery and look at how the use of specialized methods to confirm cellular identity provides a level of validation that has not previously been available

 
CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.